Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13‐week, randomized trial
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This trial evaluated the efficacy and safety of pregabalin dosed twice daily (BID) for relief of neuro-pathic pain associated with postherpetic neuralgia (PHN). RESEARCH DESIGN AND METHODS: The 13-week, double-blind, placebo-controlled study randomized 370 patients with PHN to pregabalin (150, 300, or 600 mg/day BID) or placebo. MAIN OUTCOME MEASURES: Primary efficacy measure was endpoint mean pain score from daily pain diaries. Secondary efficacy measures included endpoint mean sleep-interference score from daily sleep diaries and Patient Global Impression of Change (PGIC). Safety evaluations included adverse events (AEs), physical and neurologic examinations, 12-lead ECG, vital signs, and laboratory testing. RESULTS: Pregabalin provided significant, dose-proportional pain relief at endpoint: difference from placebo in mean pain score, 150 mg/day, -0.88, p = 0.0077; 300 mg/day, -1.07, p = 0.0016; 600 mg/day, -1.79, p = 0.0003. Weekly mean pain scores significantly improved as early as week 1. Sleep interference in all pregabalin groups was also significantly improved at endpoint, compared with placebo (p < 0.001), beginning at week 1 (p < 0.01). At study termination, patients in the 150 (p = 0.02) and 600 mg/day (p = 0.003) groups were more likely to report global improvement than were those in the placebo group. Most AEs were mild or moderate. Among pregabalin-treated patients, 13.5% withdrew due to AEs, most commonly for dizziness (16 patients, 5.8%), somnolence (8, 2.9%), or ataxia (7, 2.5%). CONCLUSIONS: Pregabalin, dosed BID, reduced neuropathic pain associated with PHN and was well tolerated. It also reduced the extent to which pain interfered with sleep. Pregabalin's effects were seen as early as week 1 and were sustained throughout the 13-week study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Self-citationRowbotham, M. (1998) · JAMA · doi:10.1001/jama.280.21.1837 · Cited by 1,433
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial
Dworkin, R. H., Corbin, A. E., Young, J. P., Sharma, U., LaMoreaux, L., Bockbrader, H., Garofalo, E. A., & Poole, R. M. (2003) · Neurology · doi:10.1212/01.wnl.0000055433.55136.55 · Cited by 768
Self-citationRosenstock, J., Tuchman, M., LaMoreaux, L., & Sharma, U. (2004) · Pain · doi:10.1016/j.pain.2004.05.001 · Cited by 725
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study
Rice, A. S. C., & Maton, S. (2001) · Pain · doi:10.1016/s0304-3959(01)00407-9 · Cited by 596
Freynhagen, R., Strojek, K., Griesing, T., Whalen, E., & Balkenohl, M. (2005) · Pain · doi:10.1016/j.pain.2005.02.032 · Cited by 572
Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial
Lesser, H., Sharma, U., LaMoreaux, L., & Poole, R. M. (2004) · Neurology · doi:10.1212/01.wnl.0000145767.36287.a1 · Cited by 570
Amitriptyline versus placebo in postherpetic neuralgia
Watson, C. P., Evans, R. J., Reed, K., Merskey, H., Goldsmith, L., & Warsh, J. (1982) · Neurology · doi:10.1212/wnl.32.6.671 · Cited by 559
Sabatowski, R., Gálvez, R., Cherry, D. A., Jacquot, F., Vincent, E., Maisonobe, P., & Versavel, M. (2004) · Pain · doi:10.1016/j.pain.2004.01.001 · Cited by 527
Self-citation
Cited by
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
The evidence for pharmacological treatment of neuropathic pain
Finnerup, N. B., Sindrup, S. H., & Jensen, T. S. (2010) · Pain · doi:10.1016/j.pain.2010.06.019 · Cited by 1,045
Recommendations for the management of herpes zoster
Dworkin, R. H., Johnson, R. W., Breuer, J., Gnann, J. W., Levin, M. J., Backonja, M., Betts, R. F., Gershon, A. A., Haanpää, M. L., McKendrick, M. W., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510206 · Cited by 869
Pregabalin for acute and chronic pain in adults
Moore, R. A., Straube, S., Wiffen, P. J., Derry, S., & McQuay, H. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub2 · Cited by 762
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690
O'Connor (2009) · doi:10.2165/00019053-200927020-00002 · Cited by 438
A Comprehensive Algorithm for Management of Neuropathic Pain
Bates, D., Schultheis, B. C., Hanes, M. C., Jolly, S. M., Chakravarthy, K. V., Deer, T. R., Levy, R. M., & Hunter, C. W. (2019) · Pain Medicine · doi:10.1093/pm/pnz075 · Cited by 401
Pregabalin for neuropathic pain in adults
Derry, S., Bell, R. F., Straube, S., Wiffen, P. J., Aldington, D., & Moore, R. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub3 · Cited by 364
Pregabalin: Its Pharmacology and Use in Pain Management
Gajraj, N. M. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000287643.13410.5e · Cited by 343
Freeman, R., Durso-DeCruz, E., & Emir, B. (2008) · Diabetes Care · doi:10.2337/dc07-2105 · Cited by 322
Farrar, J. T., Troxel, A. B., Stott, C., Duncombe, P., & Jensen, M. P. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.011 · Cited by 252
Crofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P., Martin, S. A., Haig, G. M., & Sharma, U. (2008) · Pain · doi:10.1016/j.pain.2008.02.027 · Cited by 236
“Based on the likelihood of such a shared pathway and the efficacy of pregabalin (Lyrica ) for treating neuropathic pain [7,11,17,23–25,28,31], a clinical program for treatment of pain associated with FM was undertaken.”
BackgroundResultSelf-citationOnakpoya, I. J., Thomas, E. T., Lee, J. J., Goldacre, B., & Heneghan, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023600 · Cited by 132
Farrar, J. T., Troxel, A. B., Haynes, K., Gilron, I., Kerns, R. D., Katz, N. P., Rappaport, B. A., Rowbotham, M. C., Tierney, A. M., Turk, D. C., et al. (2014) · Pain · doi:10.1016/j.pain.2014.05.009 · Cited by 110
Cepeda, M. S., Berlin, J. A., Gao, C. Y., Wiegand, F., & Wada, D. R. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01340.x · Cited by 71
Arnold, L. M., McCarberg, B. H., Clair, A. G., Whalen, E., Thomas, N., Jorga, A., Pauer, L., Vissing, R., & Park, P. W. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1384691 · Cited by 27
“1008–149 [21] (Placebo, n = 96) 12-week (11-week, BID) 150 (n = 99) 75 150 150 150 150 150 150 150 150 150 300 (n = 112) 75 150 150 225 225 225 300 300 300 300 600 (n = 88) 75 150 225 300 400 500 600 600 600 600 1008–173 [22] (Placebo, n = 30) 12-week (11-week, BID) 150 (n = 34) 75 150 150 150 150 150 150 150 150 150…”
Raskin, P., Huffman, C., Yurkewicz, L., Pauer, L., Scavone, J. M., Yang, R., & Parsons, B. (2016) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000254 · Cited by 25
Young, J. L. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.007 · Cited by 23
Self-citationParsons, B., Emir, B., & Knapp, L. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000100 · Cited by 20
Does duration of neuropathic pain impact the effectiveness of pregabalin?
Pérez, C., Latymer, M., Almas, M., Ortiz, M., Clair, A., Parsons, B., & Varvara, R. (2017) · Pain Practice · doi:10.1111/papr.12469 · Cited by 19
Metadata
- Authors
- van Seventer, R., Feister, H. A., Young, J. P., Stoker, M., Versavel, M., & Rigaudy, L.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2006-01-17
- Volume
- 22
- Issue
- 2
- Pages
- 375-384
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2158523533
- Cited by
- 264
- References
- 30
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.